Jackwood M W
Department of Avian Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602, USA.
Adv Vet Med. 1999;41:517-22. doi: 10.1016/s0065-3519(99)80038-x.
The use of biotechnology to create recombinant viral vaccines holds many promises for the future. But, to be practical, new vaccines must have a selective advantage over traditional vaccines. A vaccine that is novel because it is a recombinant vaccine is not enough. Recombinant vaccines must be safer, or more efficacious, or less expensive to produce in order for them to gain a niche in the marketplace.
利用生物技术制造重组病毒疫苗对未来有着诸多前景。但是，要切实可行，新型疫苗必须比传统疫苗具有选择性优势。仅因为是重组疫苗而新颖是不够的。重组疫苗必须更安全、更有效或生产成本更低，才能在市场上占据一席之地。
